History

SNAP-8 was developed by Lipotec (later acquired by Lubrizol) as an extended, longer analog of its earlier wrinkle peptide Argireline (Acetyl Hexapeptide-8), adding two amino-acid residues. Both peptides were patterned on the N-terminal end of SNAP-25, a SNARE-complex protein required for releasing acetylcholine at the neuromuscular junction — the same protein botulinum toxin targets. It is registered as a cosmetic ingredient (INCI name Acetyl Octapeptide-3) and carries PubChem CID 71587832, molecular formula C42H72N16O15S, and a molecular weight of about 1073 g/mol (PubChem lists 1073.2 g/mol).

SNAP-8 is a cosmetic peptide marketed as a needle-free, “Botox-like” treatment for expression wrinkles. The mechanistic idea is the same one behind its better-known relative Argireline, and on paper it is plausible. But the human efficacy numbers attached to SNAP-8 come from the manufacturer’s own small, mostly unblinded studies, no independent blinded trial appears to exist, and a stubborn skin-penetration problem casts doubt on whether the molecule can reach the target its mechanism depends on.

What it is

SNAP-8 is a synthetic octapeptide — eight amino acids, acetylated and amidated at its ends. Its INCI name is Acetyl Octapeptide-3 and its trade name is SNAP-8, developed by Lipotec (now Lubrizol). It carries PubChem CID 71587832, molecular formula C42H72N16O15S, a molecular weight of about 1073 g/mol (PubChem lists 1073.2 g/mol), and CAS number 868844-74-0.

It is an extended analog of Argireline (Acetyl Hexapeptide-8), with two extra residues. (One naming note: “Acetyl Hexapeptide-3” is an older, deprecated INCI name for the same Argireline molecule; the current INCI name is Acetyl Hexapeptide-8. Both refer to the same parent peptide.) Both SNAP-8 and Argireline are sequences patterned on the N-terminal end of SNAP-25, one of the core SNARE-complex proteins required for the vesicular release of acetylcholine at the neuromuscular junction.

The proposed mechanism is the same pathway botulinum toxin acts on, approached differently. By mimicking SNAP-25, SNAP-8 is claimed to competitively interfere with assembly of the SNARE complex, reducing acetylcholine release and thereby dampening the facial-muscle contraction that produces dynamic wrinkles. The action is proposed to be reversible and competitive rather than the enzymatic cleavage that botulinum toxin performs. This mechanism is well described in cell and biochemical systems for the peptide family — but it has not been confirmed to occur in human skin for SNAP-8.

The claims

SNAP-8 is sold as a topical cosmeceutical active, appearing in skincare products and as raw “research” or “cosmetic” powder. The headline marketing claim is “Botox-like” wrinkle reduction without injections. The widely repeated figures are roughly a 35% wrinkle reduction (versus about 27% for Argireline), or “up to ~63% wrinkle-depth reduction at 28 days.” As shown below, these numbers trace back to the manufacturer’s own technical literature, not to independent trials.

What the evidence actually shows

Human data for SNAP-8 specifically is thin and not independent. The commonly cited efficacy figures trace back to Lipotec/Lubrizol technical literature, including a small, unblinded study of roughly 17 women. The independent ingredient database INCIDecoder corroborates that the ~34.98% versus ~27.05% comparison and the n≈17, 28-day, twice-daily 10% study design are the manufacturer’s own comparison — and notes that, unlike the better-studied Argireline, SNAP-8’s efficacy rests on the manufacturer’s claim. No peer-reviewed, independent, blinded randomized or split-face trial of SNAP-8 appears in PubMed. The percentage claims should be treated as vendor data, not validated efficacy.

In vitro and delivery work exists but does not establish clinical benefit. Baglamis, Feyzioglu-Demir and Akgöl (Polymer Bulletin, 2023) reported an in vitro nanoparticle controlled-release study aimed at improving acetyl octapeptide-3 delivery. That is a formulation and delivery paper, not a human efficacy trial.

Permeability is a genuine, unresolved limitation. For the closely related parent peptide Acetyl Hexapeptide-8, a 2025 peer-reviewed review in the International Journal of Molecular Sciences found conflicting skin-penetration data — one study reported about 30% crossing the stratum corneum in two hours, while another found only about 0.22%, with nothing reaching the receptor compartment at 24 hours. The review concluded these peptides reach the epidermis but have “a low chance of penetrating the dermis,” and critically that no in vivo study confirmed the claimed inhibition of muscle contraction. These large, hydrophilic peptides do not readily cross intact skin, which undercuts the “reaches the neuromuscular junction” rationale. The same caveats apply at least as strongly to the larger SNAP-8.

The bottom line on evidence: the molecular mechanism is plausible and documented for the peptide family in cell and biochemical systems, but human clinical benefit for SNAP-8 specifically rests on small, manufacturer-funded, mostly unblinded data. Independent confirmation that it meaningfully relaxes facial muscles in living skin is absent. The credible human evidence is effectively missing.

Legal and regulatory status

SNAP-8 is a cosmetic ingredient only. It is sold as a topical cosmeceutical active in skincare and as raw “research” or “cosmetic” powder. It is not an approved drug, has no FDA drug approval, and is not a dietary supplement. In the EU it is a registered cosmetic ingredient (CosIng/INCI listed). Marketing it as “Botox-like” is a cosmetic claim, not a statement of regulatory equivalence — unlike approved drugs in this general space, SNAP-8 has never been through drug-approval trials.

On anti-doping: SNAP-8 is a topical cosmetic peptide with no performance or ergogenic rationale. It is not named on the WADA Prohibited List (verified against the 2026 list, in force 1 January 2026) and does not fall under the metabolic-modulator class (S4.4) or SARM class (S1.2). There is no plausible doping use. Athletes can verify any product through Global DRO, but there is no SNAP-8-specific listing to flag.

Safety

There is no serious safety signal in the literature, but there is also no rigorous long-term human safety dataset. As a topical cosmetic at low concentrations it is generally regarded as well tolerated; reported issues are nonspecific, such as local irritation or contact dermatitis possible with any leave-on serum.

The caveats matter. Real-world products vary widely in concentration and formulation, and “research-grade” or DIY raw powder is unregulated for purity and sterility. Because robust independent efficacy data are lacking, claims of Botox-equivalent results are not supported. There is no established safety or efficacy basis for any injected use — SNAP-8 is a topical cosmetic only. None of this is medical advice.

Bottom line

SNAP-8 has a clever, botulinum-toxin-inspired mechanism and a reasonable topical safety profile at low concentrations. But the eye-catching wrinkle-reduction percentages come from the manufacturer’s own small, unblinded studies, no independent blinded trial appears to exist, and lab data on the closely related parent peptide show these molecules barely cross intact skin — with no in vivo proof they relax muscle. Treat SNAP-8 as a low-risk cosmetic ingredient whose “topical Botox” claim is unproven, not as a validated wrinkle treatment or a substitute for injectable botulinum toxin.

Evidence grade: No credible evidence.

SNAP-8 (Acetyl Octapeptide-3)